Cubist Announces First Patient Dosed in Pivotal Global Phase III Trial of CXA-201 for Complicated Urinary Tract Infections

Cubist Pharmaceuticals announced the initiation of a pivotal Phase III trial of CXA-201 in patients with complicated urinary tract infections. CXA-201 is being developed as a first-line intravenous therapy for the treatment of serious Gram-negative bacterial infections in the hospital, including those caused by multi-drug resistant Pseudomonas aeruginosa.
Benzinga